Loading organizations...
§ Private Profile · Beijing, China
Kangjun Capital is an investment firm.
Kangjun Capital operates as an investment firm, actively engaging in the venture ecosystem by providing capital to developing companies. The firm has been identified as a participant in significant financing rounds, contributing to the growth and expansion of its portfolio entities.
Yes, Kangjun Capital has led venture funding rounds, including one that raised USD 20.83 million and another significant financing round with participation from medical industry funds.
Kangjun Capital is classified as a private equity firm, actively engaging in investment activities across various companies.
Yes, Kangjun Capital has led venture funding rounds, including one that raised USD 20.83 million and another significant financing round with participation from medical industry funds.
Kangjun Capital is classified as a private equity firm, actively engaging in investment activities across various companies.
Kangjun Capital has 2 tracked investments across 2 companies. The latest tracked deal is $72.3M Venture Round in Cascade in February 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 10, 2026 | Cascade | $72.3M Venture Round | Zhongping Capital | China Life Capital, Gaorong Capital, Qingdao Guoxin, Qingsong Capital, Shanghai Guotou Pioneer |
| Feb 3, 2026 | Deepwise | Series A | Kangjun Capital | — |
Its investment strategy includes leading funding rounds, as evidenced by its role in a venture funding round that raised USD 20.83 million, with participation from entities such as AstraZeneca CICC Healthcare. Kangjun Capital also led another financing round that included the AstraZeneca CICC Medical Industry Fund, Guofang Innovation, and Panlin Capital, indicating a focus on the medical and healthcare sectors.
Kangjun Capital has invested in companies such as Pure Global, alongside firms like Legend Capital, Bayland Capital, and Probe Capital. Additionally, it has provided capital to Biortus Biosciences, participating with investors including Hongfeng Capital, Legend Capital, and Sherpa Healthcare.
The firm's participation in a financing round for Worg, a life science company, further highlights its engagement within the life sciences sector, alongside other investors such as DeTong Capital, Paramount Capital, and SeeSu Capital. Kangjun Capital is classified as a private equity firm.